News | August 09, 2025
Akums reports Q1 FY26 PAT at Rs. 65 Cr
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats
Subscribe To Our Newsletter & Stay Updated
